Jithma Abeykoon, M.D.

Assistant Professor in Hematology and Medical Oncology at Mayo Clinic, MN, USA. Tweets are my own.

[ECD Global Alliance @ECDGA]

Registration is now open for the 2026 Patient & Family Gathering in Birmingham, Alabama, April 29–30. Join patients, families, and caregivers to connect, learn from experts, and explore the latest research. Reserve your hotel by April 6.
https://t.co/I7wxB7HmpI

[Jithma Abeykoon, M.D. @JithmaA]

Check it out " HPV16 E6 oncoprotein promotes microhomology-mediated viral integration by increasing PolΘ protein expression | PNAS https://t.co/PlGJ9WJjp7
@pnas
MMEJ is very relevant in the pathobiology of oncogene driven malignancy. More to come!

[Aishwarya Ravindran, MD @aravindranmd]

#letstalkhistiocytosis

Join us live on March 18!

Registration is open to all
https://t.co/cJCN7UPFBy

I couldn’t be more thrilled & honored to share the stage with Dr. Jennifer Picarsic @jpcrsc to discuss the many faces of Histiocytosis diagnostics in clinical practice

[Jithma Abeykoon, M.D. @JithmaA]

@ZanwarSaurabh Phenomenal job

[Saurabh Zanwar @ZanwarSaurabh]

Finally out in press!

Multi-institutional cohort of patients with Waldenström macroglobulinemia uniformly treated with bendamustine-rituximab (BR).

⏱ Median follow-up: 5.9 years
🔹 5-year PFS: 65%
🔹 5-year OS: 87%

Key highlights:
🌟 CXCR4 mutations identify a subgroup with markedly inferior PFS despite BR
🌟 POD24 is independently associated with inferior overall survival

Huge thanks to the amazing collaborators across US and Europe.

@JithmaA @MyelomaDrKapoor @VincentRK @Myeloma_mSMART @thanosdimop @ShirleyDSa1 @jonaspaludo

https://t.co/9gnV4sUbLU

[Saurabh Zanwar @ZanwarSaurabh]

2/
#3540: High-resolution WES across WM disease states reveals TP53 and MAP3K14 alterations accumulating at relapse. Distinct CNA patterns, including BCL6 gains and strong signal of non-canonical MAPK activity in relapsed WM, define treatment-exposed and high-risk biology.

@JithmaA

[Mayo Clinic @MayoClinic]

Mayo Clinic in Rochester has been named the No. 1 smart hospital in the world by Newsweek's "World's Best Smart Hospitals 2026" and earned more No. 1 specialty rankings than any other hospital in the "World's Best Specialized Hospitals 2026" list.

More: https://t.co/M55oMjwvHs

[Leukemia Journal @LeukemiaJnl]

A comprehensive review article on the risk stratification of all plasma cell disorders by @VincentRK
@ZanwarSaurabh

Myeloma, MGUS, SMM, Amyloid, WM — all here.
Open Access. https://t.co/IHT29J26zj

[Jithma Abeykoon, M.D. @JithmaA]

Very important meeting for patients with histiocytic cancers. Consider attending https://t.co/KR2949a1Qn

[Gaurav Goyal @GauravGoyalMD]

🔁 Re-sharing a study from our group on long-term outcomes in adult LCH

🧬 Clinical phenotypes, treatment patterns, and prognostic factors
📊 219 adults | ↑ mortality vs general population esp. among <55y and multi-system disease
🔗 https://t.co/aCDpX6059V
#LCH #RareDiseases

[Thor Halfdanarson @OncoThor]

And now into the head and neck region. As expected, Dr. Katharine Price delivers an outstanding presentation on advances in head and neck cancer including KN-689. But who really benefits…? @MayoMedEd @MayoCancerCare @MayoHemeOnc

[Jithma Abeykoon, M.D. @JithmaA]

@lymphoma @LLSusa @AACR Thank you for the opportunity to present our preliminary findings related to this work. Here is the publication.

[Jithma Abeykoon, M.D. @JithmaA]

Our findings are important and open a new understanding of biology and novel way of therapy @MayoCancerCare @WitzigLab
JCI - Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma https://t.co/lKVfNhlr7W

[Jithma Abeykoon, M.D. @JithmaA]

Our findings are important and open a new understanding of biology and novel way of therapy @MayoCancerCare @WitzigLab
JCI - Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma https://t.co/lKVfNhlYXu

[Jithma Abeykoon, M.D. @JithmaA]

Redefining risk stratification in pLCH https://t.co/9LAKZAAOzI

This is a significant study that redefines risk stratification in pediatric LCH. @ECDGA @HistiocyteSoc @MayoCancerCare

[Jithma Abeykoon, M.D. @JithmaA]

@OhadOrenMDMPH @MayoCancerCare @WitzigLab Thank you so much

[Jithma Abeykoon, M.D. @JithmaA]

Our findings are important and open a new understanding of biology and novel way of therapy @MayoCancerCare @WitzigLab
JCI - Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma https://t.co/lKVfNhlr7W

[Jithma Abeykoon, M.D. @JithmaA]

Hope our findings will help to bring replication stress and MMEJ targeted therapy from bench to bedside not only for MCL but also for other oncogene driven hematologic malignancies @lymphoma @MayoLymphoma @MayoCancerCare @ECDGA @ASHClinicalNews

[Jithma Abeykoon, M.D. @JithmaA]

Replication stress and DNA damage repair pathways have not been well studied in blood cancers. Our findings show that these pathways play a major role in lymphoma biology and can be successfully exploited for therapeutic benefit.

[Jithma Abeykoon, M.D. @JithmaA]

These findings are applicable for oncogene driven cancers and our study will pave the path to bring replication stress and MMEJ targeted therapy from bench to bedside not only for MCL but also for other oncogene driven blood cancers. @AACR @ASHClinicalNews @ECDGA @MayoLymphoma

[Jithma Abeykoon, M.D. @JithmaA]

Our findings are important and open a new understanding of biology and novel way of therapy @MayoCancerCare @WitzigLab
JCI - Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma https://t.co/lKVfNhlYXu

[Jithma Abeykoon, M.D. @JithmaA]

Replication stress biology and DNA damage repair pathways are under studied in blood cancers. Our findings in @JCI highlight that these pathways are important for lymphoma biology and can be successfully exploited for therapeutic benefit.